Evotec SE (NASDAQ:EVO - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $4.30, but opened at $4.10. Evotec shares last traded at $4.09, with a volume of 94,091 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th.
Get Our Latest Analysis on Evotec
Evotec Stock Performance
The stock has a fifty day moving average of $3.66 and a 200 day moving average of $4.18. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in EVO. BNP Paribas Financial Markets purchased a new position in Evotec in the 4th quarter worth approximately $27,000. CSS LLC IL purchased a new stake in shares of Evotec during the 4th quarter worth approximately $50,000. Bank of America Corp DE raised its holdings in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec during the 4th quarter worth approximately $166,000. Finally, ABC Arbitrage SA purchased a new stake in shares of Evotec during the 1st quarter worth approximately $260,000. 5.81% of the stock is owned by hedge funds and other institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
